Nanobiotix Announced New Data At ASCO 2924, Showing 48% ORR In Evaluable Anti-PD-1 Naïve Patients (n=25); 28% ORR In Evaluable Anti-PD-1 Resistant Patients (n=25) As Per RECIST 1.1
Portfolio Pulse from Charles Gross
Nanobiotix (NASDAQ:NBTX) presented new data at ASCO 2024 from their Phase 1 Study 1100, showing promising results for their radiotherapy-activated NBTXR3 followed by anti-PD-1 immune checkpoint inhibitors in patients with advanced solid and metastatic tumors. The study showed a 48% ORR in anti-PD-1 naïve patients and a 28% ORR in anti-PD-1 resistant patients.
June 02, 2024 | 2:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nanobiotix presented new data at ASCO 2024 showing a 48% ORR in anti-PD-1 naïve patients and a 28% ORR in anti-PD-1 resistant patients for their NBTXR3 treatment. This could positively impact the stock price in the short term.
The promising data presented at a major oncology conference (ASCO 2024) is likely to boost investor confidence and positively impact the stock price of Nanobiotix in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100